Chr. Hansen gets patent for its probiotic strain in S Korea

Denmark based bioscience company, Chr. Hansen has received an important patent in South Korea on one of its most clinically documented probiotic strains named BB-12 (Bifidobacterium animalis ssp. lactis).

This strain is known worldwide for its gastrointestinal health benefits and has now also been shown to hold immunity support benefits. The patent covers the BB-12 probiotic strain for use in a method of boosting the immune response in conjunction with an influenza vaccine. However, the health benefit of this probiotic strain should be seen in a much broader perspective as several clinical studies have demonstrated the immune modulating effect of BB-12.

Apart from South Korea, Chr. Hansen holds similar patents, on the BB-12 probiotic strain for use in a method of boosting the immune response in conjunction with an influenza vaccine, in Europe and China.

Register as Visitor to CPhI China 2018!